Kv3.1 and Kv3.4, Are Involved in Cancer Cell Migration and Invasion

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Voltage-gated potassium (Kv) channels, specifically Kv3.1 and Kv3.4, are recognized oxygen sensors with established roles in hypoxia.
• The connection between Kv channels and the specific microenvironment of tumor hypoxia remains largely unexplored.
• Understanding these relationships is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the role of Kv3.1 and Kv3.4 channels in the context of tumor hypoxia.
• To determine the impact of these channels on cancer cell migration and invasion.
• To explore potential therapeutic strategies targeting Kv channels in cancer metastasis.

Main Methods:

• Assessed protein expression of Kv3.1, Kv3.4, and Kv3.3 in A549 and MDA-MB-231 cancer cell lines at varying cell densities.
• Correlated Kv channel expression with hypoxia-inducible factor-1α (HIF-1α) and reactive oxygen species (ROS) levels.
• Utilized a Kv3.1 and Kv3.4 blocker, blood depressing substance (BDS), to evaluate effects on cell proliferation, migration, and invasion.
• Investigated the impact of BDS on intracellular pH regulation and extracellular signal-regulated kinase (ERK) activation.

Main Results:

• Kv3.1 and Kv3.4 protein expression increased with cell density, mirroring HIF-1α and ROS patterns, suggesting a link to tumor hypoxia.
• Kv3.3 expression remained unchanged in A549 cells regardless of cell density.
• The Kv3.1/Kv3.4 blocker BDS did not affect cell proliferation but significantly inhibited cell migration and invasion.
• BDS treatment led to suppressed intracellular pH regulation and reduced ERK activation in high-density A549 cells.

Conclusions:

• Kv3.1 and Kv3.4 channels are implicated in tumor hypoxia-related cancer cell migration and invasion.
• Inhibition of Kv3.1 and Kv3.4 channels disrupts key cellular processes, including pH regulation and ERK signaling.
• Kv3.1 and Kv3.4 channels represent promising novel therapeutic targets for combating cancer metastasis.